Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.59 |
| ▸ | CA2 | P00918 | 3/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA7 | P43166 | 2/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | PNMT | P11086 | 8/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3803914 | 1.00 | CA1 (0.59) | CA1CA2CA12CA7CA14 | |
| SCHEMBL8370641 | 0.87 | PNMT (0.49) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL6558753 | 0.85 | CA12 (0.61) | CA1CA2CA12CA7CA14 | |
| SCHEMBL6202191 | 0.82 | DRD2 (0.58) | CA1CA2CA12CA7CA14 | |
| SCHEMBL3441770 | 0.82 | PNMT (0.50) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL27744228 | 0.82 | ADRA2A (0.50) | CA1CA2CA12CA7CA14 | |
| SCHEMBL9716393 | 0.81 | PNMT (0.55) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL9716433 | 0.80 | PNMT (0.54) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL2076586 | 0.79 | WDR5 (0.51) | CA1CA2CA12CA7CA14 | |
| SCHEMBL6560917 | 0.79 | GAA (0.54) | CA1CA2CA12CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101952266-A | Compound (R)-N*6*-ethyl-6,7-dihydro-5H-indeno [5,6-d] thiazole-2,6-diamines and as the purposes of antipsychotic drug | ASTRAZENECA AB | 2011-01-19 | — | — | CN | disclosed |
| WO-2009105026-A1 | COMPOUND (R) -N*6*-ETHYL-6, 7-DIHYDRO-5H-INDENO (5, 6- D) THIAZOLE-2, 6-DIAMINE AND THE USE AS ANTIPSYCHOTICS | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | WO | disclosed |
| US-20090215841-A1 | D2 Receptor Ligand-078 | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-4963587-A | ANTICOAGULANT | TANABE SEIYAKU CO., LTD. (JP) | 1990-10-16 | — | — | US | disclosed |
| EP-0377977-A1 | Glycine derivatives and preparation thereof | TANABE SEIYAKU CO., LTD. (JP) | 1990-07-18 | — | — | EP | disclosed |
| US-4192888-A | Pharmaceutical compositions and method of inhibiting phenylethanolamine N-methyltransferase | SMITHKLINE CORPORATION (US) | 1980-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215841-A1 | D2 Receptor Ligand-078 | TACR2, TACR1, GPR174 | CA1 2762/4885CA2 2828/4885CA12 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.